ArticleEvidence-based complementary and alternative medicine : eCAM2022
Ameliorative Potential of Resveratrol in Dry Eye Disease by Restoring Mitochondrial Function.
Article in Evidence-based complementary and alternative medicine : eCAM, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 1 synthesis or guideline pooled it, 9 citations in OpenAlex.
- Global research hotspots and trends in anti-inflammatory studies in dry eye: a bibliometric analysis (2004-2024).Frontiers in medicine · 2024Pooled it
- Decoding dry eye disease based on bioinformatics and in vitro experimental: the role of immune responses and natural product intervention.Human genomics · 2026Article
- Beneficial Effects of Natural Bioactive Compounds on Eye Health: A Narrative Review.International journal of molecular sciences · 2026Review
- Mitochondrial ROS in Retinal Neurodegeneration: Thresholds, Quality Control Failure, and Precision Therapeutic Windows.Biomolecules · 2026Review
- Tear-Based Oxidative Stress Biomarkers in Primary and Sarcoidosis-Associated Dry Eye Disease.International journal of molecular sciences · 2026Article
- Hyperosmolarity-Induced Oxidative Stress Leads to Senescence in Human Corneal Epithelial Cells (HCEPC) via DNA Damage, Metabolic Disturbance and Mitophagy Decline.Antioxidants (Basel, Switzerland) · 2025Article
- Dry Eye Disease and Psychiatric Disorders: Neuroimmune Mechanisms and Therapeutic Perspectives.International journal of molecular sciences · 2025Review
- Potential New Target for Dry Eye Disease-Oxidative Stress.Antioxidants (Basel, Switzerland) · 2024Review
- In-Situ Thermoresponsive Hydrogel Containing Resveratrol-Loaded Nanoparticles as a Localized Drug Delivery Platform for Dry Eye Disease.Antioxidants (Basel, Switzerland) · 2023Article
- Resveratrol for dry eye disease - Hope or Hype?Indian journal of ophthalmology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Methods: The mitochondrial dysfunction of HCE-2 human corneal epithelial cells was induced by high osmotic pressure exposure and treated with resveratrol (50 Results: In hypertonic conditions, the apoptosis of HCE-2 cells increased, the expression of the antioxidant proteins SOD2 and GPx decreased, ROS production increased, and the expression of SIRT1 protein, an essential regulator of mitochondrial function, was downregulated. Treatment with resveratrol reversed the mitochondrial dysfunction mediated by high osmotic pressure. In the DED mouse model, resveratrol treatment promoted tear production and goblet cell number in DED mice, decreased corneal fluorescein staining, upregulated SIRT1 expression, and induced SOD2 and GPx expression in DED mice. Conclusion: Resveratrol alleviates mitochondrial dysfunction by promoting SIRT1 expression, thus reducing ocular surface injury in mice with dry eye. This study suggests a new path against DED.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.